These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 20832546

  • 21. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, Egbuna O, Rodrigue JR, Chudzinski RE, Goldfarb-Rumyantzev AS, Hanto DW, Curry MP.
    Clin Transplant; 2009; 23(6):887-96. PubMed ID: 19681971
    [Abstract] [Full Text] [Related]

  • 22. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation.
    Campbell MS, Rai J, Kozin E, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Rajender Reddy K.
    Clin Transplant; 2007; 21(3):377-84. PubMed ID: 17488388
    [Abstract] [Full Text] [Related]

  • 23. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors.
    Niel OR, Berthoux F, Albano L, Dahan P, Aoudia R, Gugenheim J, Cassuto E.
    Transplant Proc; 2009 Oct; 41(8):3329-32. PubMed ID: 19857743
    [Abstract] [Full Text] [Related]

  • 24. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL, Daly FE, O'Kelly P, O'Leary E, Deady S, O'Neill JP, Dudley A, Rutledge NR, McCormick A, Houlihan DD, Williams Y, Morris PG, Ni Raghallaigh S, Moloney FJ, Sexton DJ, Conlon PJ.
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [Abstract] [Full Text] [Related]

  • 25. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
    Signorell J, Hunziker T, Martinelli M, Koestner SC, Mohacsi PJ.
    Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
    [Abstract] [Full Text] [Related]

  • 26. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [Abstract] [Full Text] [Related]

  • 27. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S, Kramer MR, Fox B, Rusanov V, Fruchter O, Rosengarten D, Bakal I, Medalion B, Raviv Y.
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [Abstract] [Full Text] [Related]

  • 28. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
    Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP.
    Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
    [Abstract] [Full Text] [Related]

  • 29. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 30. [Conversion to rapamycin in liver transpant recipients with renal insufficiency].
    Yu S, He XS, Ma Y, Hu AB, Wu LW, Zhu XF.
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2276-8. PubMed ID: 19923086
    [Abstract] [Full Text] [Related]

  • 31. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 32. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 33. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
    Bajjoka I, Hsaiky L, Brown K, Abouljoud M.
    Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
    [Abstract] [Full Text] [Related]

  • 34. The Effect of Mammalian Target of Rapamycin Versus Calcineurin Inhibitor-based Immunosuppression on Measured Versus Estimated Glomerular Filtration Rate After Orthotopic Liver Transplantation.
    Zitta S, Schaffellner S, Gutschi J, Meinitzer A, Kniepeiss D, Artinger K, Reibnegger G, Rosenkranz AR, Wagner D.
    Transplantation; 2015 Jun; 99(6):1250-6. PubMed ID: 25606796
    [Abstract] [Full Text] [Related]

  • 35. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 36. The variable pathology of kidney disease after liver transplantation.
    Kim JY, Akalin E, Dikman S, Gagliardi R, Schiano T, Bromberg J, Murphy B, de Boccardo G.
    Transplantation; 2010 Jan 27; 89(2):215-21. PubMed ID: 20098285
    [Abstract] [Full Text] [Related]

  • 37. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 38. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
    Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, Genyk Y, Mateo R, Gagandeep S, Sher LS, Ramicone E, Fong TL.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):513-20. PubMed ID: 16441472
    [Abstract] [Full Text] [Related]

  • 39. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial.
    Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M.
    Transplantation; 2010 Dec 27; 90(12):1581-9. PubMed ID: 21030905
    [Abstract] [Full Text] [Related]

  • 40. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 27; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.